http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EA-201700155-A1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4409 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-644 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-36 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4409 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4965 |
| filingDate | 2015-10-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2017-10-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | EA-201700155-A1 |
| titleOfInvention | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF TUBERCULOSIS |
| abstract | The invention relates to the field of pharmaceuticals, specifically to the pharmaceutical composition of anti-TB drugs for the treatment of tuberculosis, including multidrug-resistant tuberculosis (MDR-TB). The technical result is to increase the efficiency of treatment of patients with tuberculosis, reduce toxicity, dosage and quantity of the name of the drugs used, reduce the time of treatment with the elimination of harmful side reactions of the drugs used. This is achieved by the fact that in a known pharmaceutical composition for treating tuberculosis, containing at least two active anti-tuberculosis agents from the first and second row, as well as pharmaceutically acceptable excipients, disintegrants, powders, it is proposed to additionally introduce an auxiliary agent that is treated electromagnetic oscillations with a frequency of 10-3000 Hz mixture prepared on the basis of sugar, honey, invert sugar, sodium citrate, formic acid and l vulinovoy acid in the following ratio: 1: 1: 0.04: 0.04: 0.04: 0,04-1: 1: 700: 200: 40: 200. The auxiliary agent is used in a syrup-like form. The use of the claimed group of the pharmaceutical composition provides a high therapeutic effect in the treatment of tuberculosis, including multidrug-resistant tuberculosis. |
| priorityDate | 2014-10-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 20.